Onyx Pharmaceuticals, Inc.

The end of each year brings a surge in venture capital funding announcements as biopharmaceutical companies and investors seek to close as many deals as possible before everyone takes off for the Dece

San Francisco start-up 3T Biosciences came out of stealth mode on 25 August with $40m in new venture capital from a series A round led by Westlake Village BioPartners with participation from Lightsp

[ Editor's note: This article originally appeared in Informa's Scrip . ] Drug-delivery specialist Halozyme Therapeutics, Inc. will buy Antares Pharma, Inc. for $960m in a buyout intended to exp

Drug delivery specialist Halozyme Therapeutics, Inc. will buy Antares Pharma, Inc. for $960m in a buyout intended to expand the company's portfolio with its first commercial products and an auto-i